Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CB-011 · 1 trial · 1 indication
Number of patients with DLTs during the 28 days following the first administration of CB-011.
The ORR will be evaluated by International Myeloma Working Group (IMWG) criteria.
| Arm | Type | Description |
|---|---|---|
| CB-011 | EXPERIMENTAL | * Part A Escalation with CB-011 in ascending doses using a traditional 3+3 design. * Part B Expansion. Up to 30 participants will be enrolled to receive CB-011 at the RDE/MTD and/or RP2D determined in Plan A |
| Name | Type | Description |
|---|---|---|
| CB-011 | BIOLOGICAL | CB-011 allogeneic CAR T cell therapy targeting BCMA Cyclophosphamide Chemotherapy for lymphodepletion Fludarabine Chemotherapy for lymphodepletion |
Inclusion Criteria: 1. Documented diagnosis of relapsed/refractory multiple myeloma (MM) with measurable disease (according to IMWG diagnostic criteria.) 2. Received at least 3 prior MM treatment lines of therapy which must include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and a...
Top 20 of 26 competitors